Tricida, Inc., founded in 2013, specializes in developing non-absorbed therapies for kidney-related diseases. Their lead product candidate, veverimer (also known as TRC101), is an orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. Metabolic acidosis, a common complication of CKD, can lead to increased mortality, accelerated kidney deterioration, muscle breakdown, and bone disease. Tricida's approach aims to slow the progression of CKD by binding and removing acid from the gastrointestinal tract.